Q BioMed Inc. and Mannin Research Inc. Sign Definitive License Agreement

By


NEW YORK—Q BioMed Inc. (OTC Pink: QBIO), a biotechnology acceleration company has signed a definitive license, with the option to acquire, the platform technology assets of Mannin Research Inc., a biotechnology company leading the development of a new class of vascular therapeutics.

The drug development program at Mannin is led by Mannin's chief scientific officer, Dr. Susan E. Quaggin, chief of the Division of Nephrology and director of the Feinberg Cardiovascular Research Institute at Northwestern University in Chicago. Utilizing a proprietary research platform, this technology is addressing the need for a new class of drugs to treat diseases such as glaucoma and Cystic Kidney disease. “Our primary target indication is for a first-in-class therapeutic eye-drop for the treatment of glaucoma in adults and children,” Q BioMed said.

QBioMed CEO Denis Corin stated, "We are extremely pleased to have closed on our initial technology transaction. This novel and exciting platform presents multiple opportunities and a pipeline of potential therapeutics including treatments for glaucoma and cystic kidney disease. We look forward to working with Dr. Quaggin, her team at Northwestern University, and Dr. George Nikopoulos, Mannin Research's CEO. We thank them for taking this step with us."

“Together with Mannin, we are developing a unique molecule delivered in an easy-to-administer eye drop designed to repair the normal flow of fluid in the eye resulting in the reduction of intra-ocular pressure, one of the main causes of glaucoma. Our platform is both unique and first-in-class and we are the only company targeting this mechanism of action,” according to Q BioMed.